Octaplaslg (Human Plasma Protein)

Octaplaslg is a plasma‑derived protein concentrate that acts on the coagulation cascade to restore deficient clotting factors.

• Massive transfusion protocols: provides balanced replacement of clotting factors to achieve hemostasis.
• Liver transplantation: supports coagulation during the peri‑operative period.
• Cardiac surgery with cardiopulmonary bypass: helps maintain adequate clotting function.

• Octaplaslg contains pooled human plasma proteins, including all vitamin K‑dependent clotting factors (II, VII, IX, X) and fibrinogen. When infused intravenously, it replenishes deficient factors, enabling the normal cascade of thrombin generation and fibrin clot formation, thereby restoring hemostatic balance in patients with coagulopathy.

Adverse reactions to Octaplaslg are generally related to its plasma origin and infusion process.

Common Side Effects

• Fever: mild temperature elevation during or after infusion.
• Chills: transient shaking sensation.
• Headache: mild to moderate discomfort.
• Nausea: occasional upset stomach.
• Hypotension: slight drop in blood pressure.
• Allergic rash: localized skin redness.

Serious or Rare Side Effects

• Anaphylaxis: severe, potentially life‑threatening allergic reaction.
• Transfusion‑related acute lung injury (TRALI): acute respiratory distress.
• Severe hemolysis: rapid destruction of red blood cells.
• Disseminated intravascular coagulation (DIC): uncontrolled clotting and bleeding.
• Viral transmission: risk of blood‑borne pathogen infection.
• Bacterial contamination: sepsis from contaminated product.

When using Octaplaslg, clinicians should observe several safety measures.

• Verify patient identity and indication: confirm need for plasma‑derived factor replacement.
• Monitor vital signs: watch for hypotension, fever, or allergic signs during infusion.
• Assess coagulation status: perform baseline and post‑infusion labs.
• Use compatible blood products: avoid mixing with incompatible plasma.
• Document adverse events: report any reactions per pharmacovigilance guidelines.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplaslg may interact with other therapies that affect hemostasis or immune response.

Major Interactions (Avoid)

• Anticoagulants (e.g., heparin, warfarin): may counteract clotting factor replacement.
• High‑dose immunoglobulins: increase risk of volume overload.

Moderate Interactions (Monitor Closely)

• Platelet inhibitors (e.g., aspirin, clopidogrel): require careful monitoring of bleeding risk.
• Fibrinolytic agents (e.g., alteplase): may diminish clot stability.
• Other plasma products: risk of cumulative volume overload.
• Cytokine‑modulating drugs: potential for enhanced immune reactions.